PUK13 FEXAPOTIDE TRIFLUTATE VERSUS PHARMACOTHERAPY AS INITIAL THERAPY FOR PATIENTS WITH MODERATE-TO-SEVERE BENIGN PROSTATE HYPERPLASIA: A COST-EFFECTIVENESS ANALYSIS